Your browser doesn't support javascript.
loading
Comparative membrane incorporation of omega-3 fish oil triglyceride preparations differing by degree of re-esterification: A sixteen-week randomized intervention trial.
Minton, Scott T; Almada, Anthony L; Evans, Joseph L; Laidlaw, Maggie; Opheim, Joar.
Afiliación
  • Minton ST; Department of Research, Nordic Naturals, Inc., Watsonville, California, United States of America.
  • Almada AL; Vitargo Global Sciences, Inc., Dana Point, California, United States of America.
  • Evans JL; P and N Development Ventures, Saint Louis, Missouri, United States of America.
  • Laidlaw M; Nutrasource Diagnostics Inc., Guelph, Ontario, Canada.
  • Opheim J; Department of Research, Nordic Naturals, Inc., Watsonville, California, United States of America.
PLoS One ; 18(1): e0265462, 2023.
Article en En | MEDLINE | ID: mdl-36706088
ABSTRACT

BACKGROUND:

Fish oil is routinely concentrated into unmodified triglycerides, or trans-esterified into an ethyl ester form. Re-esterification of the ethyl ester form yields re-esterified triglycerides (rTG), which are reportedly more bioavailable than ethyl ester forms. However, the fidelity of the re-esterification process may yield variable triglyceride forms, with only 55-60% being rTG.

OBJECTIVE:

To determine whether the blood lipidomic response to supplementation with two rTG supplements, varying by degree of re-esterification, would differ between treatments.

DESIGN:

This was a double-blind, parallel-design, single-center, 128-day study with sixty young, healthy subjects randomized into two groups. One group received a >95% rTG (Ultimate Omega®), as 1,000 mg capsules containing 325 mg eicosapentaenoic acid (EPA) and 225 mg docosahexaenoic acid (DHA), and the other received a <70% rTG (MEG-3) as 1,000 mg capsules containing 300 mg EPA and 200 mg DHA. Total intake was 2,750 and 2,500 mg EPA+DHA for the Ultimate Omega® and MEG-3 groups, respectively, with blood drawn at 4, 16 and 24 weeks and analyzed for serum and erythrocyte phospholipid fatty acid (PLFA) content.

RESULTS:

For erythrocyte PLFA profiles, EPA, docosapentaenoic acid (DPA) and DHA percentage of total erythrocyte PLFA were significantly greater for the Ultimate Omega® group than for the MEG-3 group, at week 16 (P < 0.05), as were the EPAarachidonic acid (AA) ratio, DHAAA ratio and EPA+DHAAA ratio. For serum PLFA profiles, increases in EPAAA ratio and EPA+DHAAA ratio were significantly greater at week 4 in the Ultimate Omega® group compared to the MEG-3 group (P < 0.05).

CONCLUSIONS:

These data suggest that the percentage of rTG in rTG fish oil preparations may evolve as a new chemoprofile/quality control marker that can influence its lipidomic pharmacodynamics. Additional investigations to assess the physiologic/vascular and metabolic/inflammasome responses to concentrated fish oil preparations differing in the percentage of rTG are warranted.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Aceites de Pescado / Ácidos Grasos Omega-3 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Aceites de Pescado / Ácidos Grasos Omega-3 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos